涂俊,杨娟,刘景丽,瞿广桥

• 1:武汉科技大学附属孝感医院肿瘤科

摘要(Abstract)：

目的探讨紫杉醇或白蛋白结合型紫杉醇联合表柔比星治疗晚期乳腺癌的临床疗效及不良反应。方法选取62例晚期乳腺癌患者,按照随机对照双盲的原则将其分为治疗组和对照组各31例,其中治疗组采用白蛋白结合型紫杉醇(260 mg/m~2)联合表柔比星(75 mg/m~2)治疗,对照组采用紫杉醇(175 mg/m~2)联合表柔比星(75mg/m~2)治疗。治疗2个周期后,观察比较两组患者的临床疗效及不良反应发生情况。结果治疗组的治疗总有效率93.5%(29/31)高于对照组的71.0%(22/31),差异具有统计学意义(χ~2=5.420,P=0.020)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论与紫杉醇联合多柔比星比较,白蛋白结合型紫杉醇联合表柔比星治疗晚期乳腺癌疗效好且不良反应可耐受。

关键词(KeyWords)： 乳腺肿瘤/药物疗法;表柔比星/投药和剂量;表柔比星/治疗应用;药物疗法,联合;紫杉酚/投药和剂量;紫杉酚/类似物和衍生物;血清白蛋白;双盲法;治疗结果

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 涂俊,杨娟,刘景丽,瞿广桥

DOI: 10.13267/j.cnki.syzlzz.2017.02.015

参考文献(References)：

• [1]Edwards BK,Noone AM,Mariotto AB,et al.Annual report to the nation on the status of cancer,1975-2010,featuring prevalence of comorbidity and impact on survival among persons with lung,colorectal,breast or prostate cancer[J].Cancer,2014,120(9):1290-1314.
• [2]Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:Revised RECIST guideline(version1.1)[J].Eur J Cancer,2009,45(2):228-247.
• [3]World Health Organization.WHO handbook for reporting results of cancer treatment[M].Geneva:Offset Publication,1979:48.
• [4]杨思福,黄建瑾.吉西他滨联合长春瑞滨治疗耐药性晚期乳腺癌疗效观察[J].实用肿瘤杂志,2015,30(5):462-464.
• [5]Nahleh ZA,Barlow WE,Hayes DF,et al.SWOG S0800(NCI CDR0000636131):addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response(p CR)rates in inflammatory or locally advanced breast cancer[J].Breast Cancer Res Treat,2016,158(3):485-495.
• [6]Miolo G,Muraro E,Caruso D,et al.Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer[J].Oncotarget,2016,7(26):39809-39822.
• [7]Ley J,Wildes TM,Daly K,et al.Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel[J].Med Oncol,2017,34(2):28.
• [8]黄香,吴昊,李薇,等.曲妥珠单抗联合紫杉醇脂质体和卡培他滨治疗HER-2阳性复发转移性乳腺癌[J].实用肿瘤杂志,2016,31(6):550-554.
• [9]Yamamoto Y,Kawano I,Iwase H.Nab-paclitaxel for the treatment of breast cancer:efficacy,safety and approval[J].Onco Targets Ther,2011,4(1):123-136.
• [10]姚志伟,秦科宇,王宇翀,等.纳米紫杉类药物在乳腺癌治疗中的研究现状[J].现代生物学进展,2016,16(21):4177-4180.
• [11]Desai N,Trieu V,Damascelli B,et al.SPARC expression correlates with tumor reponse to albumin-bound paclitaxel in head and neck cancer patients[J].Transl Oncol,2009,2(2):59-64.
• [12]Ueno NT,Mamounas EP.Neoadjuvant nab-paclitaxel in the treatment of breast cancer[J].Breast Cancer Res Treat,2016,156(3):427-440.
• [13]Gradishar WJ,Tjulandin S,Davidson N,et al.PhaseⅢtrial of nanoparticle albumin-bound paclitaxel compared with polyethlated castor oil-based paclitaxel in women with breast cancer[J].J Clin Oncol,2005,23(31):7794-7803.
• [14]Guan ZZ,Li QL,Feng FY,et al.Superior efficacy of a Cremophor-free albumin-bound paclitaxel with solvent based paclitaxel in Chinese patients with metastatic breast cancer[J].Asian Pac J Clin Oncol,2009,5(3):165-174.
• [15]Gradishar WJ,Karsnojon D,Cheporov S,et al.Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer[J].J Clin Oncol,2009,27(22):3611-3619.
• [16]NCCN.New NCCN guidelines include evidence blocks to illustrate value in breast,colon,kidney,and rectal cancers[J].J Natl Compr Canc Netw,2016,14(3):149-155.